FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947884939> ?p ?o ?g. }

• W2947884939 abstract "2048 Background: Cytomegalovirus (CMV) antigens have been reported in over 90% of GBM tumors. CD4 + and CD8 + T cells are most frequently directed against the gB and pp65 antigens, respectively, and are immunogenic targets in a CMV-based GBM vaccine. Methods: We have initiated a phase I/IIa clinical trial for patients with recurrent GBM using gB/pp65 enveloped virus-like particles (eVLPs) formulated with GM-CSF and administered intradermally. Subjects are vaccinated monthly until tumor progression, with immunomonitoring performed 2 weeks after each vaccination and MRI exams every 6 weeks. In phase I, eligible patients were age 18-70 with Karnofsky Performance Status at least 70, normal end-organ function, on stable or decreasing corticosteroids of at most 4mg dexamethasone (or equivalent), with recurrent GBM following any standard initial therapy and any number of recurrences. The primary endpoint was safety/tolerability and secondarily to assess immunogenicity. Three vaccine doses (0.4µg, 2µg, and 10µg pp65) were evaluated with 6 subjects in each cohort and DSMB safety review of the first 3 subjects in each cohort prior to enrolling additional subjects. Results: The DSMB identified no DLTs or safety concerns with any of the doses. Grade 2, 3 or 4 AEs occurred in 66%, 22% and 11% of participants, respectively, but were not related to vaccine administration. Twelve men and 6 women were enrolled with a median age 54 (range 39-66). Prior therapies included radiotherapy, temozolomide, and nivolumab. Immunological analyses demonstrate robust boosting of CMV-specific antibody titers and T cell responses against both gB and pp65 antigens in some but not all subjects, across all dose cohorts. Boosting of IFN-gsecreting T cells (measured by ELISPOT) exceeded the assay threshold for several subjects. Stable disease by MRI of 3 months or greater has been observed in 2 subjects in the high dose cohort and 1 subject in the low dose cohort and may correlate with vaccine response. Conclusions: The phase IIa extension phase of the trial planned to begin in Q2 2019 is designed to explore efficacy in an additional 10 subjects that will receive the optimal vaccine dose and includes the additional requirements of unifocal, measurable enhancing tumor 1-3 cm across at first recurrence and no prior immunotherapy. Clinical trial information: NCT03382977." @default.
• W2947884939 created "2019-06-07" @default.
• W2947884939 creator A5017186738 @default.
• W2947884939 creator A5021656597 @default.
• W2947884939 creator A5054857949 @default.
• W2947884939 creator A5057541817 @default.
• W2947884939 creator A5059965175 @default.
• W2947884939 creator A5086008177 @default.
• W2947884939 creator A5087754052 @default.
• W2947884939 date "2019-05-20" @default.
• W2947884939 modified "2023-09-30" @default.
• W2947884939 title "Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)." @default.
• W2947884939 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.2048" @default.
• W2947884939 hasPublicationYear "2019" @default.
• W2947884939 type Work @default.
• W2947884939 sameAs 2947884939 @default.
• W2947884939 citedByCount "2" @default.
• W2947884939 countsByYear W29478849392020 @default.
• W2947884939 crossrefType "journal-article" @default.
• W2947884939 hasAuthorship W2947884939A5017186738 @default.
• W2947884939 hasAuthorship W2947884939A5021656597 @default.
• W2947884939 hasAuthorship W2947884939A5054857949 @default.
• W2947884939 hasAuthorship W2947884939A5057541817 @default.
• W2947884939 hasAuthorship W2947884939A5059965175 @default.
• W2947884939 hasAuthorship W2947884939A5086008177 @default.
• W2947884939 hasAuthorship W2947884939A5087754052 @default.
• W2947884939 hasConcept C126322002 @default.
• W2947884939 hasConcept C143998085 @default.
• W2947884939 hasConcept C159047783 @default.
• W2947884939 hasConcept C166957645 @default.
• W2947884939 hasConcept C2776194525 @default.
• W2947884939 hasConcept C2776957806 @default.
• W2947884939 hasConcept C502942594 @default.
• W2947884939 hasConcept C71924100 @default.
• W2947884939 hasConcept C95457728 @default.
• W2947884939 hasConceptScore W2947884939C126322002 @default.
• W2947884939 hasConceptScore W2947884939C143998085 @default.
• W2947884939 hasConceptScore W2947884939C159047783 @default.
• W2947884939 hasConceptScore W2947884939C166957645 @default.
• W2947884939 hasConceptScore W2947884939C2776194525 @default.
• W2947884939 hasConceptScore W2947884939C2776957806 @default.
• W2947884939 hasConceptScore W2947884939C502942594 @default.
• W2947884939 hasConceptScore W2947884939C71924100 @default.
• W2947884939 hasConceptScore W2947884939C95457728 @default.
• W2947884939 hasLocation W29478849391 @default.
• W2947884939 hasOpenAccess W2947884939 @default.
• W2947884939 hasPrimaryLocation W29478849391 @default.
• W2947884939 hasRelatedWork W1965696789 @default.
• W2947884939 hasRelatedWork W1996322297 @default.
• W2947884939 hasRelatedWork W2078791896 @default.
• W2947884939 hasRelatedWork W2132586491 @default.
• W2947884939 hasRelatedWork W2339147068 @default.
• W2947884939 hasRelatedWork W2508692381 @default.
• W2947884939 hasRelatedWork W2588761076 @default.
• W2947884939 hasRelatedWork W2590205041 @default.
• W2947884939 hasRelatedWork W2600660754 @default.
• W2947884939 hasRelatedWork W2891416969 @default.
• W2947884939 hasRelatedWork W2891628739 @default.
• W2947884939 hasRelatedWork W2941126865 @default.
• W2947884939 hasRelatedWork W2953494693 @default.
• W2947884939 hasRelatedWork W2986788024 @default.
• W2947884939 hasRelatedWork W2987136825 @default.
• W2947884939 hasRelatedWork W2987969589 @default.
• W2947884939 hasRelatedWork W3088384805 @default.
• W2947884939 hasRelatedWork W3138607192 @default.
• W2947884939 hasRelatedWork W3167478751 @default.
• W2947884939 hasRelatedWork W3212190631 @default.
• W2947884939 isParatext "false" @default.
• W2947884939 isRetracted "false" @default.
• W2947884939 magId "2947884939" @default.
• W2947884939 workType "article" @default.